From BigGo Finance · BigGo Finance · · 50s
L&C Bio's ₩144.7 Billion Rights Offering Fully Subscribed
L&C Bio's rights offering fully subscribed by shareholders, raising ₩150.35 billion for global expansion.
In brief
L&C Bio's rights offering fully subscribed by shareholders, raising ₩150.35 billion for global expansion. L&C Bio's ₩144.7 billion rights offering fully subscribed by shareholders, raising ₩150.35 billion for Dongtan production center and overseas growth. Originally reported by BigGo Finance.
Subscription Results
L&C Bio achieved 103.92% subscription rate in its ₩144.7 billion rights offering, exceeding target shares.
Final Subscription Amount
Final subscription reached ₩150.35 billion, surpassing target raise of ₩144.67 billion.
Proceeds Allocation
72.6% of proceeds, or ₩105 billion, allocated to Dongtan Integrated Center construction.
Earnings Growth
First-half revenue reached ₩69.1 billion, up 80.6% year-over-year with positive operating profit.
Overseas Expansion
Secured UAE import approval and signed U.S. supply agreement worth at least $60 million.
Next Steps
Bonus issue scheduled for listing on next month's 12th with record date on 27th.
The bottom line
L&C Bio's ₩144.7 billion rights offering fully subscribed by shareholders, raising ₩150.35 billion for Dongtan production center and overseas growth.
